
OR WAIT null SECS
© 2025 MJH Life Sciences™ and Pharmaceutical Commerce - Biopharma Business News, Market Insights. All rights reserved.
This episode of Pharma Pulse explores how regulators modernize safety information for hormone therapy, new data that reinforces SGLT2 inhibitors’ clinical value, and Arsenal Capital expanding its life sciences logistics portfolio with the ThermoSafe acquisition.
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and in today’s headlines, HHS announces a label change for menopausal hormone therapies or hormone replacement therapies following an FDA request, researchers look to uncover both the relative and absolute effects of SGLT2is, and Arsenal Capital Partners acquires ThermoSafe.
That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.
Thanks for listening—until next time, stay well and stay informed.
You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.
Related Content: